Diagnosis and treatment of Alzheimer's disease

Screening or diagnosis of Alzheimer's disease (AD) in subject, determining stage or severity of AD, identifying subject at risk of developing AD, or monitoring effect of therapy administered to subject having AD, by analyzing body fluid to generate two-dimensional array of Alzheimer's dise...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SNYDER, PETER JEFFREY, HERATH, HERATH MUDIYANSELAGE ATHULA CHANDRASIRI, SILBER, B. MICHAEL, PAREKH, RAJESH BHIKHU, SOARES, HOLLY DARIA, KIMMEL, LIDA H, POTTER, DAVID M, TOWNSEND, ROBERT REID, ROHLFF, CHRISTIAN, WHITE, W. FROST, STIGER, THOMAS R, FRIEDMAN, DAVID L, SUNDERLAND, P. TREY, WILLIAMS, STEPHEN A, DURHAM, L. KATHRYN
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Screening or diagnosis of Alzheimer's disease (AD) in subject, determining stage or severity of AD, identifying subject at risk of developing AD, or monitoring effect of therapy administered to subject having AD, by analyzing body fluid to generate two-dimensional array of Alzheimer's disease-Associated Features (AFs) such as AF-200, AF-201, AF-202, AF-203, AF-204, AF-205, etc., and comparing abundance of AFs with control. Screening or diagnosis (M1) of Alzheimer's disease (AD) in a subject, determining (M2) the stage or severity of AD in a subject, identifying (M3) subject at risk of developing AD, or monitoring (M4) the effect of therapy administered to subject having AD, involves: (a) analyzing a test sample of body fluid from the subject by two-dimensional electrophoresis to generate a two-dimensional array of features, which comprises one or more of the Alzheimer's disease-Associated Features (AFs) given in the specification; and (b) comparing the abundance of the AFs with a body fluid sample from subjects free from AD, or with a previously determined reference range for that feature in subjects free from AD, or with the abundance at least one Expression Reference Feature (ERF) in the test sample. The method alternatively involves quantitatively detecting, in a body fluid sample, one or more of the Alzheimer's disease-Associated Protein Isoforms (APIs), given in the specification. Independent claims are also included for the following: (1) a composition (I) comprising an API, or nucleic acid encoding an API, and a carrier; (2) an antibody (II) capable of immunospecifically binding to a API; (3) a kit (K1) comprising one or more (II) and/or one or more APIs, other reagents and instructions for use; (4) a composition comprising (II), or a fragment or derivative of (I) and a carrier; (5) use of APIs and/or nucleic acid encoding API in the manufacture of a medicament for treating or preventing AD; (6) use of nucleic acid that inhibits the function of one or more of APIs in the manufacture of a medicament for treating or preventing AD; (7) screening (M5) for agents that interact with APIs, fragments of APIs (API fragment), polypeptides related to APIs (API related polypeptide), or API-fusion proteins, comprising: (a) contacting an API, a fragment of an API, an API-related polypeptide, or an API-fusion protein with a candidate agent; and (b) determining if the candidate agent interacts with the API, the fragment of an API, the API related polypeptide, or th